Composition for use as a medicament in a combination therapy to treat or reduce the risk of contracting a disorder selected from the group consisting of breast cancer, endometrial cancer, uterine cancer and ovarian cancer, the composition comprising: a) a Sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-eno-3β, 17β-diol, 4-androstene-3, 17-dione and a prodrug that becomes in vivo in any of the above sex steroid precursors and b) a therapeutically effective amount of a selective estrogen receptor modulator that is a benzopyran derivative, wherein the prodrug converted in vivo into a sex steroid precursor has the general formula: wherein X is selected from the group consisting of H-, ROC-, RCO2CHRa- and RbSO2- (R being selected from the group consisting of hydrogen, C1-C18 alkyl) al or branched, straight or branched chain (C2-C18) alkenyl, straight or branched chain (C2-C18) alkynyl, aryl, furyl, straight or branched chain (C1-C18) alkoxy, (C2-C18) alkenyloxy straight or branched chain, straight or branched (C2-C18) alkynyloxy, aryloxy, furyloxy and halogen or carboxyl analogs of the foregoing； Ra being hydrogen or (C1-C6) alkyl and Rb being selected from the group consisting of hydroxyl (or salts thereof), methyl, phenyl and p-toluyl)； in which Y is the carbonyl oxygen or Y represents a β-OX (having X the same meaning as above) and α-H and in which the selective estrogen receptor modulator has the following formula: in which R1 and R2 are independently hydrogen, hydroxyl or a moiety that is converted to hydroxyl in vivo； in which Z is a remainder of bivalent closure； in which R10 is a bivalent moiety that separates L from ring B by 4-10 intervening atoms； where L is a bivalent or trivalent polar moiety selected from the group -SO-, -CON-, -N <；and - SON <；； wherein G1 is selected from the group consisting of hydrogen, a C1 to C5 hydrocarbon or a bivalent moiety linking G2 with L to form
